2月24日，联康生物科技集团(00690)盘中上涨10.71%，截至10:51，报0.062元/股，成交119.42万元。
联康生物科技集团有限公司专注于生物创新药、高值仿制药、医美新原料及CMO四大战略领域的研发、生产、销售，旨在满足中国对优质医疗保健解决方案的需求。此外，该公司还积极与香江集团等知名公司进行战略合作，通过战略合作及引入协议授权模式来扩大产品组合，并将继续投入提升产品质量和供应链安全性，以满足国内老龄化和人口增长趋势带来的医疗需求。
截至2024年中报，联康生物科技集团营业总收入2.5亿元、净利润6149.82万元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.